(BMY) Bristol-Myers Squibb - Ratings and Ratios
Oncology, Hematology, Immunology, Neuroscience, Cardiovascular
BMY EPS (Earnings per Share)
BMY Revenue
Description: BMY Bristol-Myers Squibb
Bristol-Myers Squibb Company is a global biopharmaceutical leader with a diverse portfolio of innovative treatments across various therapeutic areas, including oncology, hematology, immunology, cardiovascular, and neuroscience. The companys product lineup includes several blockbuster drugs, such as Eliquis, Opdivo, and Revlimid, which drive revenue growth and help address significant unmet medical needs.
Key performance indicators (KPIs) that highlight the companys strengths include its robust pipeline of investigational therapies, a strong track record of R&D productivity, and a solid balance sheet with significant cash reserves. With a market capitalization of approximately $95.7 billion, Bristol-Myers Squibb has a market presence that enables it to negotiate favorable partnerships and collaborations. The companys return on equity (ROE) of 31.93% indicates efficient use of shareholder capital.
The companys diversified revenue streams are derived from a range of products, including Eliquis, which is a leading anticoagulant, and Opdivo, a top-selling immuno-oncology therapy. Other key products include Revlimid, an oral immunomodulatory drug for multiple myeloma, and Pomalyst/Imnovid, also used to treat multiple myeloma. The companys newer products, such as Abecma and Breyanzi, are CAR-T cell therapies that have shown significant promise in treating various hematological malignancies.
To drive future growth, Bristol-Myers Squibb is likely to focus on expanding its product portfolio through strategic acquisitions, partnerships, and internal R&D efforts. The companys ability to successfully execute on its pipeline and bring new therapies to market will be critical in driving long-term value creation for shareholders. Key areas of focus may include advancing its immuno-oncology franchise, developing new treatments for cardiovascular and neurological disorders, and leveraging its expertise in cell therapy to drive innovation.
BMY Stock Overview
| Market Cap in USD | 95,421m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 1972-01-01 |
BMY Stock Ratings
| Growth Rating | -22.1% |
| Fundamental | 73.1% |
| Dividend Rating | 63.7% |
| Return 12m vs S&P 500 | -15.0% |
| Analyst Rating | 3.37 of 5 |
BMY Dividends
| Dividend Yield 12m | 5.04% |
| Yield on Cost 5y | 4.77% |
| Annual Growth 5y | 0.94% |
| Payout Consistency | 93.6% |
| Payout Ratio | 36.6% |
BMY Growth Ratios
| Growth Correlation 3m | -9.4% |
| Growth Correlation 12m | -39.5% |
| Growth Correlation 5y | -32.3% |
| CAGR 5y | -1.88% |
| CAGR/Max DD 5y | -0.04 |
| Sharpe Ratio 12m | 1.17 |
| Alpha | -2.26 |
| Beta | 0.005 |
| Volatility | 30.62% |
| Current Volume | 7870.7k |
| Average Volume 20d | 10293.3k |
| Stop Loss | 45.4 (-3.2%) |
| Signal | -2.42 |
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (5.05b TTM) > 0 and > 6% of Revenue (6% = 2.86b TTM) |
| FCFTA 0.15 (>2.0%) and ΔFCFTA 1.72pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 11.94% (prev 7.79%; Δ 4.14pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.17 (>3.0%) and CFO 15.90b > Net Income 5.05b (YES >=105%, WARN >=100%) |
| Net Debt (38.33b) to EBITDA (15.09b) ratio: 2.54 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.21 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (2.04b) change vs 12m ago 0.44% (target <= -2.0% for YES) |
| Gross Margin 61.74% (prev 56.12%; Δ 5.61pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 50.39% (prev 49.14%; Δ 1.25pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 4.33 (EBITDA TTM 15.09b / Interest Expense TTM 1.98b) >= 6 (WARN >= 3) |
Altman Z'' 1.76
| (A) 0.06 = (Total Current Assets 33.22b - Total Current Liabilities 27.53b) / Total Assets 94.68b |
| (B) 0.17 = Retained Earnings (Balance) 16.15b / Total Assets 94.68b |
| (C) 0.09 = EBIT TTM 8.57b / Avg Total Assets 94.66b |
| (D) 0.19 = Book Value of Equity 14.89b / Total Liabilities 77.19b |
| Total Rating: 1.76 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 73.06
| 1. Piotroski 6.50pt = 1.50 |
| 2. FCF Yield 11.03% = 5.0 |
| 3. FCF Margin 30.56% = 7.50 |
| 4. Debt/Equity 2.83 = -0.52 |
| 5. Debt/Ebitda 3.27 = -2.10 |
| 6. ROIC - WACC 5.31% = 6.63 |
| 7. RoE 29.57% = 2.46 |
| 8. Rev. Trend 63.84% = 3.19 |
| 9. Rev. CAGR 3.31% = 0.41 |
| 10. EPS Trend -14.09% = -0.35 |
| 11. EPS CAGR -5.35% = -0.67 |
What is the price of BMY shares?
Over the past week, the price has changed by -3.20%, over one month by -1.33%, over three months by +1.12% and over the past year by +0.05%.
Is Bristol-Myers Squibb a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BMY is around 45.83 USD . This means that BMY is currently overvalued and has a potential downside of -2.24%.
Is BMY a buy, sell or hold?
- Strong Buy: 4
- Buy: 4
- Hold: 18
- Sell: 0
- Strong Sell: 1
What are the forecasts/targets for the BMY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 53 | 13.1% |
| Analysts Target Price | 53 | 13.1% |
| ValueRay Target Price | 49.1 | 4.8% |
Last update: 2025-08-29 04:33
BMY Fundamental Data Overview
CCE Cash And Equivalents = 12.60b USD (last quarter)
P/E Trailing = 18.8273
P/E Forward = 7.3153
P/S = 2.0003
P/B = 5.5605
P/EG = 2.2562
Beta = 0.372
Revenue TTM = 47.70b USD
EBIT TTM = 8.57b USD
EBITDA TTM = 15.09b USD
Long Term Debt = 44.47b USD (from longTermDebt, last quarter)
Short Term Debt = 4.91b USD (from shortTermDebt, last quarter)
Debt = 49.38b USD (Calculated: Short Term 4.91b + Long Term 44.47b)
Net Debt = 38.33b USD (from netDebt column, last quarter)
Enterprise Value = 132.20b USD (95.42b + Debt 49.38b - CCE 12.60b)
Interest Coverage Ratio = 4.33 (Ebit TTM 8.57b / Interest Expense TTM 1.98b)
FCF Yield = 11.03% (FCF TTM 14.58b / Enterprise Value 132.20b)
FCF Margin = 30.56% (FCF TTM 14.58b / Revenue TTM 47.70b)
Net Margin = 10.58% (Net Income TTM 5.05b / Revenue TTM 47.70b)
Gross Margin = 61.74% ((Revenue TTM 47.70b - Cost of Revenue TTM 18.25b) / Revenue TTM)
Tobins Q-Ratio = 8.88 (Enterprise Value 132.20b / Book Value Of Equity 14.89b)
Interest Expense / Debt = 0.98% (Interest Expense 485.0m / Debt 49.38b)
Taxrate = 25.94% (from quarterly Income Tax Expense: 460.0m / 1.77b)
NOPAT = 6.35b (EBIT 8.57b * (1 - 25.94%))
Current Ratio = 1.21 (Total Current Assets 33.22b / Total Current Liabilities 27.53b)
Debt / Equity = 2.83 (Debt 49.38b / last Quarter total Stockholder Equity 17.43b)
Debt / EBITDA = 3.27 (Net Debt 38.33b / EBITDA 15.09b)
Debt / FCF = 3.39 (Debt 49.38b / FCF TTM 14.58b)
Total Stockholder Equity = 17.08b (last 4 quarters mean)
RoA = 5.33% (Net Income 5.05b, Total Assets 94.68b )
RoE = 29.57% (Net Income TTM 5.05b / Total Stockholder Equity 17.08b)
RoCE = 13.93% (Ebit 8.57b / (Equity 17.08b + L.T.Debt 44.47b))
RoIC = 9.53% (NOPAT 6.35b / Invested Capital 66.65b)
WACC = 4.22% (E(95.42b)/V(144.80b) * Re(6.03%)) + (D(49.38b)/V(144.80b) * Rd(0.98%) * (1-Tc(0.26)))
Shares Correlation 5-Years: -60.0 | Cagr: -2.10%
Discount Rate = 6.03% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 78.97% ; FCFE base≈13.92b ; Y1≈14.60b ; Y5≈17.04b
Fair Price DCF = 146.8 (DCF Value 298.80b / Shares Outstanding 2.04b; 5y FCF grow 5.25% → 3.0% )
Revenue Correlation: 63.84 | Revenue CAGR: 3.31%
Rev Growth-of-Growth: -0.20
EPS Correlation: -14.09 | EPS CAGR: -5.35%
EPS Growth-of-Growth: 35.03
Additional Sources for BMY Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle